Australia Withdraws E-cigarette Commercial Sales Plan, Allowing Non-prescription Purchase at Pharmacies

Regulations by 2FIRSTS.ai
Jun.24.2024
Australia Withdraws E-cigarette Commercial Sales Plan, Allowing Non-prescription Purchase at Pharmacies
Australia government withdraws e-cigarette sales plan, allowing non-prescription purchase at pharmacies. Health Minister Mark Butler reached agreement with Greens.

According to The Sydney Morning Herald on June 24th, the Australian government has withdrawn its plan to allow e-cigarettes to be sold commercially. E-cigarettes will not require a prescription to be purchased in pharmacies.

 

Minister of Health Mark Butler reached an agreement with the Green Party on Monday, June 24th, to relax the ban on e-cigarettes scheduled to take effect in July. This was in order to pass legislation in the Senate to prohibit retail sales, as the initially stricter proposal did not have the support of the majority of senators.

 

According to sources familiar with the agreement, after the ban on e-cigarettes takes effect in July, consumers will still need a doctor's prescription to purchase e-cigarettes. However, in the future, adults will not need a prescription from a general practitioner to buy e-cigarettes from pharmacies. They will only need to speak with a pharmacist and can purchase them over the counter.

 

At the same time, individuals under the age of 18 are allowed to purchase e-cigarettes with a prescription from a clinician if deemed appropriate.

 

The government has promised to provide additional funding to support young people in quitting e-cigarettes.

 

E-cigarettes sold in pharmacies will still be regulated and must comply with standard packaging requirements.

 

Butler's adjustment is a concession to the substantial political capital invested in the success of the e-cigarette ban. He will announce the full details of the changes later today.

 

Butler previously proposed the idea of allowing people to purchase e-cigarettes from pharmacies without a prescription, but he stated that this would only be considered if the prescription drug model is not successful.

 

He stated in November of last year,

 

Health ministers are interested in exploring whether e-cigarettes can be provided solely by pharmacists in pharmacies, where similar products are often located behind the counter and require interaction with a pharmacist but not a doctor's prescription.

 

We have not made a decision yet, but I have said that if the proposed reform does not adequately ensure that people with genuine treatment needs can access e-cigarettes, we will consider other options.

 

Both the Greens and the National Party have expressed doubt about the proposal put forward by the Labor Party to ban all retail sales of e-cigarettes and require a prescription from a general practitioner to obtain them from a pharmacy. This is a stricter version of the law first proposed by former Coalition Health Minister Greg Hunt in 2021.

 

The Green Party and the two major political parties are aligned in their desire to prevent children from purchasing e-cigarettes from unlicensed stores.

 

However, the Greens' health spokesperson, Jordon Steele-John, expressed concerns about the difficulties and costs of quitting smoking for those who need to make an appointment with a general practitioner in order to get a prescription. The Department of Health's analysis of Butler's original plan indicates that 450,000 Australians per year will seek e-cigarette prescriptions, requiring nearly one million visits to general practitioners.

 

John also expressed skepticism towards the prohibition model, pointing out that drug bans have proven to be ineffective.

 

Many young Australians are using e-cigarettes, banning the sale of e-cigarettes could potentially become a political issue.

 

No one should be punished for personal use of e-cigarettes. Prohibition policies for drugs have failed. Many people under the age of 18 are becoming addicted to nicotine. We need to ensure there are proper resources in place to help these individuals quit using e-cigarettes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
Swedish Match Faces Broader Labeling Order After ZYN Inspection, Documents Obtained by 2Firsts Show
Swedish Match Faces Broader Labeling Order After ZYN Inspection, Documents Obtained by 2Firsts Show
Documents obtained by 2Firsts show that Sweden's Public Health Agency ordered Swedish Match to revise ingredient labels beyond the five ZYN products inspected. The dispute centers on whether flavoring ingredients must be individually disclosed, with Swedish Match citing trade-secret protection and the regulator insisting on full ingredient disclosure. The company faces a conditional penalty of SEK 2 million per month for noncompliance. As of October 22, the agency had received no appeal, despite the company's stated intention to challenge the decision.
Oct.22
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Product | Philip Morris Japan Teams Up With Renowned French Audio Brand DEVIALET for Limited-Edition IQOS Priced 60% Above Standard Model
Philip Morris Japan (PMJ) launched the limited-edition IQOS ILUMA i PRIME Soundsorial Model in collaboration with French audio brand DEVIALET on October 1, 2026. Featuring sound-wave patterns, a silver-and-black finish and a gradient holder, the heated tobacco device is priced at JPY 15,980, including tax, and is available at four IQOS stores in Japan. According to Japanese media citing a PMJ representative, about 1,900 units were allocated to the Japanese retail market. A separate Soundsorial Collection, combining the device with DEVIALET Gemini II earbuds, includes 440 sets allocated to Japan for a membership prize draw.
product
Oct.23
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Four CrossBar 20K disposable e-cigarettes appeared on Pennsylvania's 163-entry ENDS directory ahead of enforcement beginning October 19, 2026. The devices feature 13mL e-liquid reservoirs, 50mg/mL nicotine, 2,000mAh batteries and 0.9Ω mesh coils, with advertised puff counts of up to 20,000. CrossBar was the only modern high-puff disposable series among the directory's 15 disposable entries. Its packaging emphasizes New York design and Japanese-origin flavoring, while historical CrossBar records identify a registered U.S. tobacco manufacturing-related establishment. The link between the newer 13mL devices and earlier 1.3mL PMTA filings remains unconfirmed.
product
Oct.26
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Couche-Tard Posts Double-Digit U.S. Same-Store Growth in Other Nicotine Products, Led by Pouches
Alimentation Couche-Tard said U.S. same-store sales in its “other nicotine products” category grew at a double-digit rate in the first quarter of fiscal 2027, led by nicotine pouches, while overall U.S. same-store merchandise revenues increased 1.7%. The company also said its Canadian nicotine business continued to face regulatory pressure and illicit-market headwinds. The U.S. performance coincides with Couche-Tard's participation in efforts to reopen Canadian convenience-store access to authorized nicotine pouches, though the company has not established a direct causal link between the two.
Sep.14